Compugen Still Confident Of Its TIGIT Strategy Despite Roche’s Setbacks
Highlights Triple Blockade Strategy And Differentiated TIGIT Molecule
Executive Summary
The small-cap biotech is not currently favored by investors but CEO Anat Cohen-Dayag tells Scrip she believes Compugen could have the optimal TIGIT strategy.
You may also be interested in...
Blow To Roche Growth Prospects As TIGIT Lung Cancer Trial Fails
Failure of the tiragolumab plus Tecentriq combination in first line NSCLC patients is a blow to Roche’s immunotherapy aspirations, and its long-term growth strategy.
Beam Therapeutics’ Base-Edited CAR-T Placed On Hold
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.
On A Roll, AstraZeneca Aims For ‘Industry-Leading’ Growth From 2025
AstraZeneca’s momentum is growing towards ‘industry-leading' revenue growth, but investors are focused on the operating margin, and concerned about when CEO Pascal Soriot will depart.